Impact of baseline and interim quantitative PET parameters on outcomes of classical Hodgkin Lymphoma

被引:0
|
作者
Fernanda Maria Santos
Jose Flavio Gomes Marin
Marcos Santos Lima
Wellington Fernandes Silva-Junior
Lucas Bassolli O. Alves
Frederico R. Moreira
Rodrigo Dolphini Velasques
Marcelo Junqueira Atanazio
Ana Carolina Arrais Maia
Carlos A. Buchpiguel
Valeria Buccheri
Vanderson Rocha
机构
[1] Faculdade de Medicina,Instituto Do Cancer Do Estado de Sao Paulo (ICESP)
[2] Universidade de Sao Paulo (FMUSP),Nuclear Medicine Medical Investigation Laboratory LIM43
[3] Hospital das Clinicas,Division of Hematology and Cell Therapy
[4] FMUSP (HCFMUSP),Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco
[5] HCFMUSP,Immuno
[6] HCFMUSP,Hematology (LIM
[7] Churchill Hospital,31), Department of Internal Medicine, Division of Hematology
[8] NHS BT,Department of Hematology
[9] Oxford University,undefined
来源
Annals of Hematology | 2024年 / 103卷
关键词
Hodgkin lymphoma; Positron emission tomography; Metabolic tumor volume; Total lesion glycolysis;
D O I
暂无
中图分类号
学科分类号
摘要
Currently, analysis of interim PET (iPET) according to the Deauville score (DS) is the most important predictive factor in Hodgkin lymphoma (HL); however, there is room for improvement in its prognostic power. This study aimed to evaluate the prognostic value of quantitative PET analysis (maximum standard uptake value [SUVmax], total metabolic tumor volume [TMTV] and total lesion glicolysis [TLG]) at baseline (PET0) and iPET in a retrospective cohort of newly diagnosed classical HL. For positive iPET (+ iPET), the reduction of quantitative parameters in relation to PET0 (ΔSUVmax, ΔTMTV and ΔTLG) was calculated. Between 2011 and 2017, 234 patients treated with ABVD were analyzed. Median age was 30 years-old, 59% had advanced stage disease, 57% a bulky mass and 25% a + iPET (DS 4–5). At baseline, high TLG was associated with an increased cumulative incidence of failure (CIF) (p = 0.032) while neither SUVmax, TMTV or TLG were associated with overall survival (OS) or progression-free survival (PFS). In multivariate analysis, only iPET was associated with CIF (p < 0.001). Among ΔSUVmax, ΔTMTV and ΔTLG, only a ΔSUVmax ≥ 68.8 was significant for PFS (HR: 0.31, CI95%: 0.11–0.86, p = 0.024). A subset of patients with improved PFS amongst + iPET was identified by the quantitative (ΔSUVmax ≥ 68.8%) analysis. In this real-world Brazilian cohort, with prevalent high-risk patients, quantitative analysis of PET0 did not demonstrate to be prognostic, while a dynamic approach incorporating the ΔSUVmax to + iPET succeeded in refining a subset with better prognosis. These findings warrant validation in larger series and indicate that not all patients with + iPET might need treatment intensification.
引用
收藏
页码:175 / 183
页数:8
相关论文
共 50 条
  • [21] Interim PET Assessment of Advanced Hodgkin Lymphoma: Is It Sufficient?
    Mesguich, Charles
    Bouabdallah, Krimo
    Bordenave, Laurence
    Milpied, Noel
    Hindie, Elif
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61 (11) : 1694 - 1695
  • [22] Semi-quantitative parameters could improve positive predictive value of interim FDG-PET/CT in Hodgkin Lymphoma
    Annunziata, S.
    Cuccaro, A.
    Hohaus, S.
    Giordano, A.
    Rufini, V.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S312 - S312
  • [23] Impact of interim PET on Hodgkin lymphoma treatment outcome and survival in clinical practice.
    Zheng, Serena
    Gupta, Kanika
    Goyal, Piyush
    Nakajima, Reiko
    Michaud, Laure
    Batlevi, Connie Lee
    Hamlin, Paul A.
    Horwitz, Steven M.
    Kumar, Anita
    Matasar, Matthew J.
    Moskowitz, Alison J.
    Moskowitz, Craig H.
    Noy, Ariela
    Palomba, Maria Lia
    Straus, David J.
    Schoder, Heiko
    Yahalom, Joachim
    Zelenetz, Andrew David
    Younes, Anas
    Joffe, Erel
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [24] The Complementary Prognostic Role of Baseline and Interim PET in Predicting Treatment Outcome in Advanced-Stage Hodgkin Lymphoma
    Cimino, Giuseppe
    Zaucha, Jan Maciej
    Cirillo, S.
    Saviolo, C.
    Hutchings, Martin
    El-Galaly, T. C.
    Borra, Anna
    Rago, Angela
    Gallamini, Andrea
    BLOOD, 2014, 124 (21)
  • [25] Reply: Interim PET Assessment of Advanced Hodgkin Lymphoma: Is It Sufficient?
    Stephens, Deborah M.
    Schoder, Heiko
    Li, Hongli
    Friedberg, Jonathan
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61 (11) : 1695 - 1695
  • [26] Prognostic value of interim PET in aggressive non Hodgkin lymphoma
    Aloj, Luigi
    Frigeri, Ferdinando
    Caraco, Corradina
    Mettivier, Laura
    Capobianco, Gaetana
    Volzone, Francesco
    Morisco, Anna
    Ibello, Francesco
    Pinto, Antonio
    Lastoria, Secondo
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (03)
  • [27] PROGNOSTIC IMPLICATION OF INTERIM PET CT IN PAEDIATRIC HODGKIN LYMPHOMA
    Boddu, Deepthi
    Apoorva, G.
    John, Rikki
    Hephzibah, Julie
    Mathew, Leni G.
    PEDIATRIC BLOOD & CANCER, 2020, 67 : S174 - S175
  • [28] PROGNOSTIC IMPACT OF INTERIM PET (PETI) IN PATIENTS WITH HODGKIN LYMPHOMA (LH): A CENTER'S EXPERIENCE
    Moreno, Velazquez Miriam
    Morgades, De la Fe Mireia
    Garcia, Caro Montserrat
    Pineda, Moron Alberto
    Vives, Polo Susana
    Batlle, Massana Montserrat
    Torrent, Catarineu Anna
    Franch, Sarto Mireia
    Canamero, Giro Eloi
    Espasa, Perez Andrea
    Comes, Escoda Martina
    Huguet, Mas Maria
    De la Fuente, Montes Cristina
    Quintela, Vilches David
    Ribera, Santasusana Josep Maria
    HAEMATOLOGICA, 2020, 105 : 407 - 407
  • [29] THE IMPACT OF OUTCOME OF INTERIM PET/CT ON ADVANCED HODGKIN LYMPHOMA TREATED WITH EACOPP-14
    Medvedovskaya, E.
    Leontjeva, A.
    Demina, E.
    Ryabukhina, J.
    Tumyan, G.
    Kokosadze, N.
    Trofimova, O.
    Larionova, V.
    Dolgushin, M.
    Odzharova, A.
    Mukhortova, O.
    Aslanidis, I.
    Osmanov, D.
    HAEMATOLOGICA, 2016, 101 : 26 - 26
  • [30] Quantitative assessment of interim PET in Hodgkin lymphoma evaluation of the qPET method in adult patients in the RAPID trial
    Georgi, Thomas
    Kurch, Lars
    Hasenclever, Dirk
    Warbey, Victoria
    Radford, John
    Sabri, Osama
    Kluge, Regine
    Barrington, Sally
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60